Holen Sie sich die Stockscreener-App
1.96
1.51%
-0.03
Handel nachbörslich:
1.99
0.03
+1.53%
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend - TradingView
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance UK
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - Stock Titan
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Access Bio Inc To Acquire 57 Billion Won Worth Of Shares And Majority Stake In Rfbio Co Ltd - TradingView
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
GRI Bio (NASDAQ: GRI) approves reverse split to support Nasdaq equity - Stock Titan
GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements - TipRanks
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Cabaletta Bio, Inc. Announces 2026 Strategic Priorities - TradingView — Track All Markets
Zura Bio Ltd Announces Corporate and Clinical Updates for 2026 - TradingView — Track All Markets
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can Boundless Bio Inc. stock double in next 5 yearsPortfolio Return Report & Expert Verified Movement Alerts - Улправда
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - Улправда
Is Mustang Bio Inc. stock positioned for long term growthQuarterly Trade Review & Growth-Oriented Investment Plans - ulpravda.ru
Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting - WV News
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - TradingView — Track All Markets
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
New drug trials target lupus and kidney disease, with 2026 data ahead - Stock Titan
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
FibroGen (NASDAQ: FGEN) rebrands as Kyntra Bio with new ticker KYNB - Stock Titan
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
How a $2 million payment wiped out $10.6 million in company debt - Stock Titan
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development - Quantisnow
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio Announces Granting of Japanese Patent Covering - GlobeNewswire
Biotech shrinks share count 16 to 1—what changes for its shareholders - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
1.65%
3.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):